Male Infertility Market Segmentation:
Distribution Channel Segment Analysis
Hospital pharmacies segment is anticipated to hold male infertility market share of over 31% by the end of 2035. The revenue growth of the segment is attributed to its significance as a primary distribution channel for essential medication and supplies. The number of pharmacies offering fertility care products has increased as the market sees growth leading to greater accessibility. In June 2024, NLM published a report on the rising demand for urologists and male fertility care. The report estimates around over 500000 men require reproductive urologist care annually leading to the rising demands for fertility care in men. Additionally, the product offerings to care for male infertility are expanding leading to greater footfall in hospital pharmacies for sell of medications such as supplements, antibiotics, hormonal therapies, and fertility drugs. The segment’s growth is projected to continue as an increasing number of males seek fertility care in hospitals leading to greater sales of male fertility care products in hospital pharmacies.
Retail pharmacies and drug stores are poised to have a considerable revenue growth during the forecast period. This segment is a vital distribution channel for male infertility products providing patients with convenient access to medications, supplements, and over the counter remedies. Retail pharmacies and drug stores offer a consumer-friendly approach to male fertility cater and are accessible to a broader demographic including men who are seeking supplemental or preventive products for early-stage infertility concerns. Due to ease of accessibility, the segment is poised for rapid growth as more males seek first line interventions such as vitamins, antioxidants, over the counter supplements. Additionally, availability of generic versions of fertility care drugs and supplements can be cost effective options for price conscious demographics boosting the segment’s growth.
Test Segment Analysis
DNA fragmentation in male infertility market segment is projected to increase its revenue share substantially during the forecast period due to rising awareness in males. It is an important biomarker for male infertility and healthcare professionals can tailor effective treatment plans by addressing underlying causes of DNA fragmentation. As early diagnosis demands for male fertility care grow, the demands for DNA fragmentation tests are poised to increase. Additionally, rising disposable income in emerging economies has made DNA fragmentation tests more accessible to males contributing to the segment’s growth. In July 2023, Medical Electronic Systems launched the QwikCheck DFI kit that is designed to make laboratory tests for DNA fragmentation quicker and easier.
Our in-depth analysis of the male infertility market includes the following segments
|
Distribution Channel |
|
|
Test |
|
|
Treatment |
|
